A
Adicet Bio
A biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer
About Adicet Bio
Adicet Bio is a biotechnology company focused on developing innovative cancer therapies. The company specializes in creating allogeneic (donor-derived) gamma delta T cell therapies, which are a type of immune cell therapy designed to target and destroy cancer cells. Unlike traditional therapies that require a patient's own cells, Adicet Bio's approach uses "off-the-shelf" cells that can be readily available for treatment, making the process faster and potentially more effective.
Read full description
Adicet Bio operates in the healthcare and biotechnology market, primarily serving patients with various types of cancer. Their clients include healthcare providers, hospitals, and research institutions that are involved in cancer treatment and research.
The company's business model revolves around the development and commercialization of its proprietary gamma delta T cell therapy technology. They invest heavily in research and development to create these therapies and then partner with healthcare providers to bring these treatments to patients. Adicet Bio generates revenue through a combination of product sales, licensing agreements, and potentially future partnerships with larger pharmaceutical companies.
Adicet Bio's recent merger with resTORbio aims to advance their technology further, combining resources and expertise to accelerate the development and commercialization of their therapies. The company has also secured significant funding, including an $80 million Series B financing round, to support its research and development efforts.
In summary, Adicet Bio is at the forefront of cancer immunotherapy, leveraging cutting-edge technology to develop readily available, genetically modified T cell therapies that target tumors. Their innovative approach has the potential to significantly improve cancer treatment outcomes.
At a glance
- Founded
- 2006
- Headquarters
- Redwood City, United States
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
OrbiMed
Novartis Venture Fund
Samsung Ventures
Pontifax Funds
Johnson & Johnson Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adicet Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adicet Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.